1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Slovenia Pharmaceuticals and Healthcare Report Q4 2015

Slovenia Pharmaceuticals and Healthcare Report Q4 2015

  • August 2015
  • -
  • Business Monitor International
  • -
  • 96 pages

Includes 3 FREE quarterly updates

BMI View: Slovenia, similar to most Central and Eastern European (CEE) countries, currently has limited
capabilities in managing its rare disease population and we expect that EU authorities will push the country into accelerating its implementation of the necessary infrastructure to manage this patient subgroup. While Slovenia has adopted a national strategy and has a more progressive attitude towards orphan drug reimbursement than many of its CEE peers, it currently lacks crucial elements needed to manage these populations. It is an area where Slovenia's healthcare system will need to expand coverage todeliver better patient outcomes.

Headline Expenditure Projections

- Pharmaceuticals: EUR675mn (USD896mn) in 2014 to EUR671mn (USD738mn) in 2015; -0.6% in local currency terms and -17.6% in US dollar terms. Forecasts unchanged compared to previous quarter.
- Healthcare: EUR3.22bn (USD4.27bn) in 2014 to EUR3.23bn (USD3.55bn) in 2015; 0.4% in local currency terms and -16.8% in US dollar terms. Forecasts unchanged compared to previous quarter.

Table Of Contents

Slovenia Pharmaceuticals and Healthcare Report Q4 2015
BMI Industry View 7
SWOT 9
Political 11
Economic 12
Operational Risk 13
Industry Forecast 15
Pharmaceutical Market Forecast 15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovenia 2011-2019) 17
Healthcare Market Forecast 18
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2011-2019) 20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2011-2019) 20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2011-2019) 20
Prescription Drug Market Forecast 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovenia 2011-2019) 22
Patented Drug Market Forecast 23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovenia 2011-2019) 25
Generic Drug Market Forecast 26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Slovenia 2011-2019) 27
OTC Medicine Market Forecast 28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovenia 2011-2019) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Slovenia 2013-2019) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovenia 2013-2019) 32
Key Risks To BMI's Forecast Scenario 33
Macroeconomic Forecasts 35
Economic Analysis 35
Real GDP By Expenditure 36
Risks To Outlook 40
Table: GDP By Expenditure (Slovenia 2012-2019) 40
Industry Risk Reward Ratings 41
Central And Eastern Europe Risk/Reward Index - Q4 2015 41
Slovenia Risk/Reward Index 47
Rewards 47
Risks 47
Market Overview 49
Industry Trends And Developments 51
Epidemiology 51
Healthcare Sector 52
Table: Healthcare Resources (Slovenia 2009-2014) 56
Table: Healthcare Personnel (Slovenia 2009-2014) 56
Table: Healthcare Activity (Slovenia 2009-2014) 57
Research and Development 57
Clinical Trials 57
Regulatory Development 59
Intellectual Property Issues 60
Pricing Regime 60
Reimbursement Regime 62
Competitive Landscape 64
Research-Based Industry 64
Generic Drugmakers 64
Pharmaceutical Industry Developments 65
Company Profile 66
Krka 66
Lek (Novartis/Sandoz) 71
GlaxoSmithKline (GSK) 75
Sanofi 77
Pfizer 79
Novartis 81
Merck and Co 83
Demographic Forecast 85
Table: Population Headline Indicators (Slovenia 1990-2025) 86
Table: Key Population Ratios (Slovenia 1990-2025) 86
Table: Urban/Rural Population and Life Expectancy (Slovenia 1990-2025) 87
Table: Population By Age Group (Slovenia 1990-2025) 87
Table: Population By Age Group % (Slovenia 1990-2025) 88
Glossary 90
Methodology 92
Pharmaceutical Expenditure Forecast Model 92
Healthcare Expenditure Forecast Model 92
Notes On Methodology 93
Risk/Reward Index Methodology 94
Index Overview 95
Table: Pharmaceutical Risk/Reward Index Indicators 95
Indicator Weightings 96

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.